Table 1

Adjusted HR (95% CI) of LEA associated with dipstick proteinuria and ACR

ExposureEvents/NPerson-yearsHR (95% CI)
Primary cohort: analysis among patients with PAD (N = 4,657); median follow-up 3.5 years (IQI 1.1–6.9 years)
Dipstick proteinuria categoryModel 1Model 2Model 3
Negative192/2,59612,781ReferenceReferenceReference
Trace56/5392,5921.38 (1.03–1.87)1.42 (1.05–1.92)1.32 (0.97–1.78)
1+77/6602,5531.74 (1.34–2.27)1.61 (1.23–2.11)1.44 (1.10–1.88)
≥2+140/8622,6692.70 (2.17–3.37)2.18 (1.69–2.80)1.70 (1.32–2.19)
Ptrend<0.001<0.001<0.001
Secondary cohort: analysis among patients with PAD and diabetes (N = 2,506); median follow-up 4.3 years (IQI 1.6–7.1 years)
ACR, mg/gModel 1Model 2Model 3
ACR <1047/6473,674ReferenceReferenceReference
ACR 10–2976/6042,9421.78 (1.25–2.54)1.74 (1.22–2.49)1.47 (1.03–2.11)
ACR 30–300113/8813,8591.96 (1.41–2.71)1.82 (1.32–2.54)1.50 (1.07–2.09)
ACR >30059/3741,3522.56 (1.77–3.72)2.14 (1.43–3.19)1.61 (1.07–2.43)
Ptrend<0.001<0.0010.02
  • Model 1: adjusted for age, sex, and race. Model 2: model 1 adjustments + baseline year, smoking, hypertension, cardiovascular disease (coronary artery disease, heart failure, or stroke), medication use (renin-angiotensin system inhibitors, antiplatelets, and statins), and eGFR. Model 3: model 2 adjustments + duration of diabetes, diabetic retinopathy, diabetic neuropathy, and HbA1c (secondary cohort only). IQI, interquartile interval.